leisure time -WSS

leisure time

author：comprehensive 2025-09-30 01:13:04 - browse：11

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

leisure time

WSS

Ionis has late

At flashy new research hub, AstraZeneca lays out ambitious growth goals

UnitedHealth argues against case alleging wrongful AI care denials

Intercept Pharmaceuticals sells itself for less than $1 billion

Address the ethical violations that led to 'Three Identical Strangers'

For longer

leisure time

leisure time

Wikipedia

Bright Health sells Medicare Advantage business to Molina

Shingles, which affected Dianne Feinstein, is on the rise

Heart attack and stroke risk calculators need revising

ASCO eve: Let’s set the table for this year's meeting

Jerome Adams on the need for new antivirals for Covid

Cue Health, Covid

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Paxlovid should be available without a positive Covid test

hotspot

Making the case for fair compensation in clinical trials

FDA seeks to regulate lab

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Health tech startups drop sharply from 2021 highs

Data show record exodus of life scientists from academia

Investigation reveals sickle cell patients pressured into sterilizations

hotspot

leisure time

explore

focus